Organogenesis Holdings (ORGO) Net Cash Flow Growth (3y) (2019 - 2026)
Organogenesis Holdings (ORGO) Net Cash Flow Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 32.03% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 28.99% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 37.89% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -49.94% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 37.74% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -41.05% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -62.71% |
| 10 | Organogenesis Holdings | 323.97 Mn | 231.87 Mn | 11.46 Mn | 45.61% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 45.61% |
| Dec 31, 2025 | 102.73% |
| Sep 30, 2025 | -23.90% |
| Jun 30, 2025 | -117.47% |
| Mar 31, 2025 | -61.99% |
| Dec 31, 2024 | 51.72% |
| Sep 30, 2024 | -28.97% |
| Jun 30, 2024 | -54.92% |
| Mar 31, 2024 | -29.85% |
| Dec 31, 2023 | -51.36% |
| Sep 30, 2023 | 63.97% |
| Jun 30, 2023 | 26.30% |
| Mar 31, 2023 | -1.43% |
| Dec 31, 2022 | -28.61% |
| Sep 30, 2022 | -53.84% |
| Jun 30, 2022 | 34.31% |
| Mar 31, 2022 | -38.40% |
| Dec 31, 2021 | 66.71% |
| Sep 30, 2021 | -20.35% |
| Jun 30, 2021 | 215.83% |